Dalbeth and coworkers studied 92 patients with gout and using DECT scanning have shown those with urate deposition on DECT were 8.5-fold more likely to have erosive disease on plain radiographs.
Researchers from the University of Manchester investigated self-reported adherence to biologic treatment in RA and found that 41% of patients were non-adherent to adalimumab therapy at least once, and 23% were nonadherent overall. http://bit.ly/1KA2
Although the cause is not clear, women who have weight loss surgery have a higher risk of thinning bones (osteoporosis) and fractures over time, according to a new analysis of a Swedish study.
25% of Medicare beneficiaries with rheumatoid arthritis use high-cost biologics. Yazdany and coworkers have analyzed a national cohort of beneficiaries and compared Medicare part D plans.
52.5 million US adults (22.7%) have arthritis with half of these claiming activity limitation because of arthritis and pain. Many arthritis patients have comorbid conditions including heart disease (49%), diabetes (47%) and obesity (31%).
IL-17 inhibitors are being developed for treatment of psoriasis, psoriatic arthritis and axial spondyloarthritis. Broadalumab has been in phase II & III trials and been developed by a partnership between Amgen and Astra-Zeneca.
A prospective study of sildenafil was conducted in 25 centers that included 83 patients and 192 digital ulcers at entry. The odds of healing ulcers was less, but not significant, for sildenafil.
Three phase III studies of sarilumab (SARIL-RA-TARGET, -EASY and -ASCERTAIN), a fully-human IL6 receptor antibody, have been reported and met primary end points in these pivotal clinical trials.
Fibromyalgia is a noninflammatory disorder. However, there are patients with prolonged morning stiffness, subjective joint swelling and many with modest-to-moderate elevations of acute-phase reactants.
A US Preventive Services Task Force recommends DEXA screening in women >65 yrs and only in women 65 yrs if there is a significan risk of fracture. Amarnath and coworkers studied 50,995 women in primary care, aged 40-85 years, between 2006-2012.
The manufacturers of the 2 best selling TNF inhibitors, Enbrel and Humira, have announced a 9.9% price increase of May 1st. The current average price of Enbrel is $42,000 per annum.
The population prevalence of Sjogrens syndrome is 0.2%, with an incidence of 4 cases per 100,000 per year. Sjogrens is 20 times more common in females than males.
By downloading this material, I acknowledge that it may be used only for personal use and personal education and that I will accredit RheumNow.com as the source and owner of this material. Commercial use or mass reproduction of this material without permission from RheumNow (info@rheumnow.com) is prohibited.
